Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Pindolol is a beta adrenoceptor antagonist used to treat hypertension, edema, ventricular tachycardias, and atrial fibrillation. Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension.
- Mechanism
- Curator reviewed · 13 references
The beta-1 adrenoceptor is a G-protein-coupled receptor. Agonism of the beta-1 adrenoceptor allows the Gs subunit to upregulate adenylyl cyclase, converting ATP to cyclic AMP (cAMP). Increased concentrations of cAMP activate cAMP-dependant kinase A, phosphorylating calcium channels, raising intracellular calcium, increasing calcium exchange through the sarcoplasmic reticulum, and increasing cardiac inotropy. cAMP-dependant kinase A also phosphorylates myosin light chains, increasing smooth muscle contractility. Increased smooth muscle contractility in the kidney releases renin.
Pindolol is a non-selective beta blocker. Blocking beta-1 adrenergic receptors in the heart results in decreased heart rate and blood pressure. By blocking beta-1 receptors in the juxtaglomerular apparatus, pindolol inhibits the release of renin, which inhibits angiotensin II and aldosterone release. Reduced angiotensin II inhibits vasoconstriction and reduced aldosterone inhibits water retention.
Beta-2 adrenoceptors located in the kidneys and peripheral blood vessels use a similar mechanism to activate cAMP-dependant kinase A to increase smooth muscle contractility. Blocking of the beta-2 adrenoceptor relaxes smooth muscle, leading to vasodilation.
- Primary indication
- Pindolol is indicated in the management of hypertension.Curator reviewed · 5 structured indications
- Formula / weight
- C14H20N2O2 · 248.3208 g/mol (avg)
- First approval
- Canada, 1993 · United States, 1982
- Code names
- BRN 1536506 · CCRIS 9215 · DL-LB-46 · HSDB 6539 · LB-46
- Brand names
- Viskazide
- Visken
Resolves to
JZQKKSLKJUAGIC-UHFFFAOYSA-NSMILESCC(C)NCC(O)COC1=CC=CC2=C1C=CN2What you can answer from here — as of September 20, 2026
Which drugs share a target with Pindolol, and which of those have an active Phase 3 trial?